Needham & Company LLC reiterated their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a report published on Monday, Benzinga reports. The firm currently has a $26.00 price objective on the stock.
PHAT has been the subject of a number of other research reports. HC Wainwright reaffirmed a buy rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday, May 10th. Stifel Nicolaus initiated coverage on shares of Phathom Pharmaceuticals in a research report on Friday, May 3rd. They issued a buy rating and a $24.00 target price for the company.
Read Our Latest Report on PHAT
Phathom Pharmaceuticals Stock Up 8.3 %
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($1.42) EPS for the quarter, topping analysts’ consensus estimates of ($1.43) by $0.01. The company had revenue of $1.91 million for the quarter, compared to the consensus estimate of $2.76 million. On average, sell-side analysts anticipate that Phathom Pharmaceuticals will post -5.57 earnings per share for the current fiscal year.
Institutional Trading of Phathom Pharmaceuticals
Several large investors have recently bought and sold shares of PHAT. China Universal Asset Management Co. Ltd. raised its holdings in Phathom Pharmaceuticals by 355.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,626 shares of the company’s stock valued at $60,000 after buying an additional 5,171 shares during the last quarter. DAVENPORT & Co LLC bought a new position in shares of Phathom Pharmaceuticals in the 4th quarter worth $91,000. Public Employees Retirement System of Ohio bought a new stake in Phathom Pharmaceuticals during the 3rd quarter valued at $92,000. Klingman & Associates LLC bought a new position in shares of Phathom Pharmaceuticals in the first quarter valued at $110,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Phathom Pharmaceuticals during the first quarter valued at about $119,000. 99.01% of the stock is owned by institutional investors and hedge funds.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Recommended Stories
- Five stocks we like better than Phathom Pharmaceuticals
- How to buy stock: A step-by-step guide for beginners
- Sales Breakout Sends This Semiconductor Stock to Record High
- Transportation Stocks Investing
- Surprise Buying Opportunity on This Dividend Aristocrat
- What is a Stock Market Index and How Do You Use Them?
- New Theme Park Powerhouse: Merger Creates Industry-Leading Stock
Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.